Home » Topics » BioWorld Science

BioWorld Science
RSS

Antabio SAS patents new antibacterial compounds

Dec. 13, 2019

DPP8 may be a target for multiple myeloma therapy by inducing apoptotic cell death

Dec. 13, 2019

New long-acting HIV-1 fusion inhibitor-based regimen developed

Dec. 13, 2019

First phase III data for YF-H-2015005 shows rapid mobilization of CD34+ cells

Dec. 13, 2019

Kaleido to advance KB-174 for HE based on topline data from study in patients with cirrhosis

Dec. 13, 2019

Soligenix initiates phase Ic study of RiVax

Dec. 13, 2019

Prescient presents promising interim phase Ib data for PTX-200 in ovarian cancer

Dec. 13, 2019

Positive interim safety data presented from ongoing phase Ib/IIa study of ATYR-1923

Dec. 13, 2019

Phase Ib data for carfilzomib plus chemotherapy in children with refractory ALL

Dec. 13, 2019

EGFL7 as a new therapeutic target in AML

Dec. 13, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...